Cas:119189-70-7 Bis-PEG6-acid manufacturer & supplier

Chemical Name:Bis-PEG6-acid

CAS.NO:119189-70-7

Synonyms:4,7,10,13,16,19-Hexaoxadocosane-1,22-dioic acid;MFCD20926399

Molecular Formula:C₁₆H₃₀O₁₀

Molecular Weight:382.403

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:543.4±50.0 °C at 760 mmHg

Density:1.2±0.1 g/cm3

Index of Refraction:1.473

PSA:

Exact Mass:382.183899

LogP:-2.26

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 4,7,10,13,16,19-Hexaoxadocosane-1,22-dioic acid chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,MFCD20926399 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,MFCD20926399 Use and application,4,7,10,13,16,19-Hexaoxadocosane-1,22-dioic acid technical grade,usp/ep/jp grade.

Related News: While they are early data, “it’s also very reassuring that those patients who have progressed can be rather easily reinduced into remission,” Tendler said. J&J and AbbVie are now taking the same approach for the GLOW study, he added. Bis-PEG6-acid manufacturer The fine and functional chemicals sector provides new growth drivers. Bis-PEG6-acid supplier Refers to the active pharmaceutical ingredients used in the manufacture of original research drugs (patent drugs or innovative drugs). It mainly meets the needs of international original research drug companies and emerging biopharmaceutical companies for innovative drugs at various stages of clinical research, registration approval and commercialization of drugs. Contains advanced intermediates used in the manufacture of this drug substance that need to be regulated by regulatory authorities. Bis-PEG6-acid vendor Refers to the active pharmaceutical ingredients used in the manufacture of original research drugs (patent drugs or innovative drugs). It mainly meets the needs of international original research drug companies and emerging biopharmaceutical companies for innovative drugs at various stages of clinical research, registration approval and commercialization of drugs. Contains advanced intermediates used in the manufacture of this drug substance that need to be regulated by regulatory authorities. Bis-PEG6-acid factory This dosage form may also support combination therapy modalities.? To date, over 400 patients have been dosed with the oral formulation of rigosertib in clinical trials.? Combination therapy of oral rigosertib with azacitidine, the standard of care in HR-MDS, has also been studied. Currently, oral rigosertib is being developed as a combination therapy together with azacitidine for patients with higher-risk MDS who require HMA therapy.?